AstraZeneca Pharma India Ltd. SWOT Analysis: Strengths, Weakness, Opportunity, and Threats| MACD Crossover Below Signal Line | |
| Inefficient use of capital to generate profits - RoCE declining in the last 2 years | -9.0% returns for Nifty 500 over 1.9 years |
| Degrowth in Revenue and Profit | |
| Major fall in TTM Net Profit |
| Companies with high market cap, lower public shareholding | |
| Stocks with Expensive Valuations according to the Trendlyne Valuation Score | 177.2% returns for Nifty 500 over 4.5 years |
| Stocks with high PE (PE > 40) |
| Expensive Performers (DVM) | 102.3% returns for over 5.4 years |
| Expensive Performers (DVM) | 79.4% returns for over 5.4 years |
| Average Financial Performers - Stocks with Medium Trendlyne Durability Score versus Benchmarks | 187.6% returns for Nifty 500 over 4.5 years |
| Average Bullish Trend - Stocks with Medium Trendlyne Momentum Score versus Benchmarks | 181.7% returns for Nifty 500 over 4.5 years |
| Top Gainers | |
| High Volume, High Gain |
Compare Stocks
